Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics

现代表型药物发现：从化学生物学到治疗学

• 批准号: 10468419
• 负责人: Thale Cross Jarvis
• 金额: $ 1.72万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-15 至 2023-04-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10468419
• 关键词: 3-Dimensional; Academia; Address; Area; Artificial Intelligence; Biological; Biological Assay; Biological Models; Biology; CRISPR/Cas technology; Cells; Chemicals; Chemistry; Clinical; Collaborations; Colorado; Communities; Data Science; Discipline; Educational workshop; Evolution; Fostering; Genes; Goals; Health; Human; Image; Industry; Knowledge; Learning; Machine Learning; Mentors; Methodology; Modeling; Modernization; Outcome; Phenotype; Physiological; Renaissance; Research; Research Personnel; Science; Scientist; Technology; Therapeutic; Translating; Work; base; career; cheminformatics; clinical practice; drug discovery; human disease; improved; induced pluripotent stem cell; innovation; interest; meetings; new technology; novel; posters; pre-clinical; programs; recruit; screening; small molecule; success; symposium; translational impact

ABSTRACT Support is requested for a Keystone Symposia conference entitled Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics, organized by Drs. Bridget Wagner, Neil Carragher, Jeremy Jenkins and Laura Kiessling. The conference will be held in Denver, Colorado from May 22-25, 2022. Phenotypic Drug Discovery (PDD) as an approach to drug discovery and chemical biology has been building momentum and excitement in both academia and industry. The convergence of new technology platforms (e.g., induced pluripotent stem cells, CRISPR-Cas9 gene editing, 3D biology, advanced imaging) with other disciplines such as cheminformatics, machine learning, and artificial intelligence have led to an exciting renaissance of PDD. This conference will bring together researchers performing or interested in phenotypic drug discovery from across academia and industry. Although modern advances in PDD span both academic and industry sectors, there are few non-commercial drug discovery-focused meetings available for the community, and the Keystone Symposia program is a premiere forum for this topic. This conference aims to share information and best practices in new PDD technologies, biological models, and human disease areas, as well as foster collaborative discussions across academia and industry. Additionally, this conference program will address several critical barriers in the field: how to improve the physiological relevance of phenotypic models and identifying a phenotypic target and understanding a compound’s mechanism of action (MoA). It is anticipated that attendees will leave with a renewed appreciation for phenotypic strategies in a wide variety of areas in chemical biology, and that the field will be advanced by expanding our collective efforts to push the boundaries of improved assay models and cutting-edge MoA technologies.

抽象的 请求支持Keystone研讨会会议，标题为“现代表型药物发现：摘自 由Drs组织的化学生物学对治疗剂。布里奇特·瓦格纳，尼尔·卡拉格，杰里米·詹金斯和 劳拉·基斯林（Laura Kiessling）。该会议将于2022年5月22日至25日在科罗拉多州的丹佛举行。 表型药物发现（PDD）作为药物发现和化学生物学的一种方法 学术界和工业的动力和兴奋。新技术平台的融合 （例如，诱导多能干细胞，CRISPR-Cas9基因编辑，3D生物学，高级成像） 化学信息学，机器学习和人工智能等学科导致了令人兴奋的 PDD复兴。这次会议将使研究人员对表型进行表现或感兴趣 从学术界和工业中发现的药物发现。尽管PDD的现代进步跨越了两位学者 和行业领域，很少有非商业毒品发现的会议可用于 社区和Keystone研讨会计划是该主题的首映论坛。这次会议旨在 在新的PDD技术，生物模型和人类疾病领域共享信息和最佳实践， 以及培养学术界和行业的协作讨论。此外，这次会议 计划将解决该领域的几个关键障碍：如何改善的身体相关性 表型模型并识别表型目标并理解化合物的作用机理 （MOA）。可以预计，与会者将对表型策略的重新感谢 化学生物学领域的各种领域，并且通过扩大我们的集体努力来推进该领域 突破改进的测定模型和尖端MOA技术的界限。